{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:24:17Z","timestamp":1793125457622,"version":"4.5.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Current guidelines recommend norepinephrine as the first-line vasopressor in septic shock followed by addition of vasopressin to achieve a goal mean arterial pressure. Limited evidence exists evaluating how the timing of vasopressin addition affects clinical outcomes in septic shock.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this study was to determine whether the timing of the addition of vasopressin to norepinephrine affects shock resolution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a multi-site, single system, retrospective cohort, institutional review board (IRB)-approved study examining adult patients with septic shock who received norepinephrine and vasopressin. Patients were divided and statistically analyzed in two subgroups: early vasopressin addition (&lt;3 hours) and late vasopressin addition (\u22653 hours). The primary outcome was time to shock resolution, defined as vasopressor free for at least 24 hours. Secondary outcomes included norepinephrine dose at 3 hours after initiation of vasopressin, in-hospital mortality, and intensive care unit length of stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 243 patients were included in this study. A statistically significant decrease in time to shock resolution was observed in the early vasopressin addition group compared to the late vasopressin addition group (37.6 hours vs 60.7 hours; adjusted hazard ratio [HR]: 2.07 [1.48-2.89;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = &lt;0.001]). The early addition of vasopressin did not affect norepinephrine dose or in-hospital mortality but did lead to a decreased intensive care unit (ICU) length of stay (4.3 days vs 5.3 days,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Addition of vasopressin to norepinephrine within 3 hours was associated with a faster time to shock resolution. These findings suggest a potential for improved clinical outcomes with earlier vasopressin addition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221118903","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T02:37:41Z","timestamp":1661827061000},"page":"521-526","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Timing of Vasopressin Addition to Norepinephrine and Efficacy Outcomes in Patients With Septic Shock"],"prefix":"10.1177","volume":"57","author":[{"given":"Allison L.","family":"Brask","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hennepin County Medical Center, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9919-1844","authenticated-orcid":false,"given":"Shelby M.","family":"Shemanski","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saint Luke\u2019s Hospital of Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler E.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saint Luke\u2019s Hospital of Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-3025","authenticated-orcid":false,"given":"Ashley K.","family":"Holmes","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saint Luke\u2019s Hospital of Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208623."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003342."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005337."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907118."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000251127.45385.CD."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000063046.82359.4A."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067373."},{"key":"e_1_3_2_9_2","unstructured":"International Classification of Diseases (ICD-10-CM\/PCS) transition-background. Centers for Disease Control and Prevention. Updated November 6 2015. Accessed July 4 2022. https:\/\/www.cdc.gov\/nchs\/icd\/icd10cm_pcs_background.htm."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0018578720946751."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066617725255."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/08850666221081836."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005317."}],"updated-by":[{"DOI":"10.1177\/10600280231151309","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000}}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221118903","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221118903","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221118903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:17:02Z","timestamp":1777375022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221118903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1177\/10600280221118903"],"URL":"https:\/\/doi.org\/10.1177\/10600280221118903","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]}}}